Orthofix Medical Inc. (NASDAQ:OFIX) Stock Holdings Boosted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its position in shares of Orthofix Medical Inc. (NASDAQ:OFIX) by 14.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 324,807 shares of the medical device company’s stock after acquiring an additional 39,901 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Orthofix Medical were worth $5,073,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of OFIX. Paradigm Capital Management Inc. NY lifted its stake in Orthofix Medical by 31.3% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after buying an additional 609,137 shares in the last quarter. Engine Capital Management LP increased its holdings in Orthofix Medical by 11.0% in the second quarter. Engine Capital Management LP now owns 3,368,665 shares of the medical device company’s stock worth $44,668,000 after buying an additional 333,364 shares during the last quarter. Marshall Wace LLP acquired a new position in Orthofix Medical in the second quarter worth approximately $2,193,000. AYAL Capital Advisors Ltd increased its holdings in Orthofix Medical by 10.2% in the second quarter. AYAL Capital Advisors Ltd now owns 686,794 shares of the medical device company’s stock worth $9,107,000 after buying an additional 63,697 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new position in Orthofix Medical in the second quarter worth approximately $832,000. Institutional investors own 89.76% of the company’s stock.

Orthofix Medical Stock Down 2.4 %

NASDAQ:OFIX opened at $18.09 on Friday. The firm has a market capitalization of $691.29 million, a price-to-earnings ratio of -5.78 and a beta of 1.09. Orthofix Medical Inc. has a twelve month low of $11.17 and a twelve month high of $20.73. The stock’s 50 day moving average price is $17.50 and its two-hundred day moving average price is $16.04. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on OFIX shares. Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and increased their price objective for the company from $18.00 to $24.00 in a research report on Friday, November 8th. Roth Mkm reissued a “buy” rating and set a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.00.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.